Form 4: Cytokinetics EVP Fady Ibraham Malik Executes Stock Options and Sells Shares
SEC Form 4
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold shares on September 17, 2024.
Summary
- On September 17, 2024, Fady Ibraham Malik, the EVP of Research & Development at Cytokinetics Inc., executed non-qualified stock options to purchase 5,300 shares of common stock at a price of $7.96 per share.
- Simultaneously, Malik sold 5,300 shares at $56.77 and 2,000 shares at $56.76.
- Following these transactions, Malik directly owns 120,920 shares of Cytokinetics common stock and 31,800 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it reports routine stock transactions by an executive. It doesn't inherently indicate positive or negative outlook for the company.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into an executive's perspective on the company's value and future prospects.
Stakeholder Impact
- Shareholders may be interested in insider transactions as an indicator of management's confidence in the company.
- The transactions themselves have a minimal direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 03/26/2015 | Date exercisable for Non-Qualified Stock Option (Right to Buy) |
| 02/26/2025 | Expiration date for Non-Qualified Stock Option (Right to Buy) |
| 09/17/2024 | Date of transaction: exercise of stock options and sale of shares. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.